Results 41 to 50 of about 82,478 (265)

Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis

Cancer Immunology and Immunotherapy, 2022
Introduction Immune checkpoint inhibitors (ICI) such as anti-PD-L1 and anti-PD-1 agents have been proven to be effective in various cancers. However, the rate of non-responders is still high in all cancer entities.
Á. Széles, T. Fazekas, S. Váncsa, M. Váradi, P. T. Kovács, U. Krafft, V. Grünwald, B. Hadaschik, A. Csizmarik, P. Hegyi, A. Váradi, P. Nyirády, T. Szarvas   +12 more
semanticscholar   +1 more source

Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia

Blood Advances, 2018
: Although immune checkpoint molecules regulate the progression of certain cancers, their significance in malignant development of Waldenstrom macroglobulinemia (WM), an incurable low-grade B-cell lymphoma, remains unknown.
Shahrzad Jalali, Tammy Price-Troska, Jonas Paludo, Jose Villasboas, Hyo-Jin Kim, Zhi-Zhang Yang, Anne J. Novak, Stephen M. Ansell   +7 more
doaj   +1 more source

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer

Frontiers in Immunology, 2022
Accumulating evidence suggests that regulatory B cells (Bregs) play important roles in inhibiting the immune response in tumors. Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) are important molecules that maintain the balance of the ...
Xuejiao Li, Xuejiao Li, Huan Du, Huan Du, Shenghua Zhan, Wenting Liu, Wenting Liu, Zhangyu Wang, Zhangyu Wang, Jing Lan, Longxiang PuYang, Yuqiu Wan, Yuqiu Wan, Qiuxia Qu, Sining Wang, Yang Yang, Qin Wang, Fang Xie   +17 more
doaj   +1 more source

Smoking Is Associated With Low Levels of Soluble PD-L1 in Rheumatoid Arthritis [PDF]

Frontiers in Immunology, 2018
Smoking is a risk factor for developing rheumatoid arthritis (RA), but the mechanism remains uncertain. We previously demonstrated that smoking lowers the T cell activation threshold by limiting programmed death protein 1 (PD-1) expression.To investigate how smoking influence the levels of soluble PD-1 ligand (sPD-L1).Serum levels of sPD-L1 were ...
Caroline Wasén, Malin C. Erlandsson, Apostolos Bossios, Linda Ekerljung, Carina Malmhäll, Sofia Töyrä Silfverswärd, Rille Pullerits, Rille Pullerits, Bo Lundbäck, Maria I. Bokarewa   +9 more
openaire   +3 more sources

Application of Lung-Targeted Lipid Nanoparticle-delivered mRNA of soluble PD-L1 via SORT Technology in Acute Respiratory Distress Syndrome

Theranostics, 2023
Rationale: Acute respiratory distress syndrome (ARDS) is a life-threatening condition characterized by excessive immune response usually due to lung inflammation. Local immunosuppression is crucial for effective ARDS treatment.
Han Sun, Yu Zhang, Jiahui Wang, Juncheng Su, Dejian Zhou, Xiang Yu, Yingjie Xu, Wen Yang   +7 more
semanticscholar   +1 more source

Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages [PDF]

Cell Death & Disease, 2020
AbstractAcute respiratory distress syndrome (ARDS) is common in intensive care units (ICUs), although it is associated with high mortality, no effective pharmacological treatments are currently available. Despite being poorly understood, the role of programmed cell death protein 1 (PD-1) and PD-ligand 1 (PD-L1) axis in ARDS may provide significant ...
Xu, Jing, Wang, Jiahui, Wang, Xiaoli, Tan, Ruoming, Qi, Xiaoling, Liu, Zhaojun, Qu, Hongping, Pan, Tingting, Zhan, Qingyuan, Zuo, Yong, Yang, Wen, Liu, Jialin   +11 more
openaire   +2 more sources

Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis

International Journal of Molecular Sciences, 2022
Blocking the Programmed Cell Death Protein 1 (PD-1)/programmed death ligand-1 (PD-L1) axis has demonstrated great efficacy in cancer immunotherapy treatment and remains the central modality of immune targeting. To support the rational and tailored use of
F. Scirocchi, L. Strigari, A. Di Filippo, C. Napoletano, A. Pace, H. Rahimi, A. Botticelli, A. Rughetti, M. Nuti, I. Zizzari   +9 more
semanticscholar   +1 more source

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy

Biomedicines, 2022
While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry has been shown to be an imperfect biomarker that only applies to a limited number of cancers, whereas many patients with PD-L1-negative tumors still respond to anti-PD-
Tao Wang, Desirée Denman, Silvia M. Bacot, Gerald M. Feldman   +3 more
doaj   +1 more source

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment

Scientific Reports, 2021
Circulating soluble programmed death-1 ligand (sPD-L1) is measurable in the serum of cancer patients. This study aimed to investigate the significance of sPD-L1 in cancer patients receiving immune checkpoint inhibitor therapy. Blood samples were obtained
So-Yeon Oh, Soyeon Kim, B. Keam, T. Kim, Dong-Wan Kim, D. Heo   +5 more
semanticscholar   +1 more source

Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis

Frontiers in Immunology, 2023
Introduction Currently, first-line immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) inhibitors, are utilized as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand-1 ...
Takashi Shimizu, Eisuke Inoue, Ryotaro Ohkuma, S. Kobayashi, Takuya Tsunoda, Satoshi Wada   +5 more
semanticscholar   +1 more source